David Harlan to Antibody Formation
This is a "connection" page, showing publications David Harlan has written about Antibody Formation.
Connection Strength
0.150
-
Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO, Cruzata F, Elster EA, Gray GS, Kampen RL, Patterson NB, Szklut P, Swanson J, Xu H, Harlan DM. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001 Aug 15; 72(3):377-84.
Score: 0.046
-
Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999 Jun; 5(6):686-93.
Score: 0.040
-
Harlan DM, Abe R, Lee KP, June CH. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin Immunol Immunopathol. 1995 May; 75(2):99-111.
Score: 0.030
-
Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 2002 Nov 27; 74(10):1365-9.
Score: 0.013
-
Elster EA, Xu H, Tadaki DK, Montgomery S, Burkly LC, Berning JD, Baumgartner RE, Cruzata F, Marx R, Harlan DM, Kirk AD. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation. 2001 Nov 15; 72(9):1473-8.
Score: 0.012
-
Horspool JH, Perrin PJ, Woodcock JB, Cox JH, King CL, June CH, Harlan DM, St Louis DC, Lee KP. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol. 1998 Mar 15; 160(6):2706-14.
Score: 0.009